Related Experiment Video
Updated: Apr 21, 2026
10:21
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
966
Proinflammatory cytokine interleukin-6 in prostate carcinogenesis
1Experimental Urology, Department of Urology, Innsbruck Medical University Anichstrasse 35, A-6020 Innsbruck, Austria.
American Journal of Clinical and Experimental Urology
|November 7, 2014
Summary
Interleukin-6 (IL-6) is a key cytokine in prostate cancer, influencing tumor growth and differentiation. While IL-6 inhibition showed promise in models, clinical trials for advanced prostate cancer yielded limited success.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Interleukin-6 (IL-6) is a pro-inflammatory cytokine implicated in prostate cancer progression.
- IL-6 signaling pathways, including JAK/STAT, MAPK, and PI3K, are activated in prostate cancer.
- IL-6 influences tumor cell proliferation, apoptosis, androgen receptor activity, and angiogenesis.
Purpose of the Study:
- To investigate the role of IL-6 in prostate cancer.
- To evaluate experimental therapies targeting IL-6 signaling in prostate cancer models and patients.
Main Methods:
- Analysis of IL-6 expression in prostate cancer specimens and cell lines.
- Investigation of IL-6-mediated signaling pathways (JAK/STAT, MAPK, PI3K).
- Evaluation of the anti-cancer effects of the IL-6 targeting monoclonal antibody CNTO328 in preclinical models and clinical trials.
Main Results:
- IL-6 expression is regulated by oncogenes and tumor suppressors in prostate cancer.
- IL-6 exhibits context-dependent effects, promoting growth in some models but inhibiting LNCaP cells.
- CNTO328 delayed castration resistance in a xenograft model but showed limited efficacy in clinical monotherapy for castration-resistant prostate cancer.
Conclusions:
- IL-6 plays a complex role in prostate cancer, affecting multiple pathways crucial for tumor progression.
- Targeting IL-6 signaling with CNTO328 demonstrates potential in preclinical settings but requires further investigation for clinical efficacy in advanced prostate cancer.
Related Concept Videos
01:25Inflammatory Bowel Disease III: Crohn's Disease
16
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
16
01:25Mutagenicity and Carcinogenicity
2.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
2.2K
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
19
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
19
01:20The JAK-STAT Signaling Pathway
14.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
14.3K